Park Lane Ventures is a venture capital firm focused on making late stage venture and growth investments in healthcare companies, primarily in the United States. Park Lane’s senior team has over 95 years of collective experience investing in and operating a variety of healthcare companies including specialty pharmaceutical, biotechnology, medical device and healthcare information technology companies.
Park Lane seeks out complex opportunities where there has been a disruption to the business trajectory (either external or internal) and where capital and Park Lane’s principals’ extensive experience and contacts can help redirect the company to a successful outcome.
Park Lane was founded by three experienced investors with a deep understanding of the healthcare industry. Below are summary professional biographies of the Principals and the other members of the Park Lane investment team.
Mr. Thangaraj is a Managing Director and Co-Founder of Park Lane.
In addition to being part of the founding team at Park Lane, Mr. Thangaraj spent 21 years at EW where he was a Managing Director of six funds and served on numerous public and private company boards related to the firm's investment activity. At EW, he focused on many areas within the firm's broad investment focus, including co-heading its medical device practice and heading up its China practice. During most of his tenure, he was the president of the management company, served as the principal liaison with limited partners and chaired its fundraising activities.
Dr. Himawan is a Managing Director and Co-Founder of Park Lane.
In addition to being part of the founding team at Park Lane, Dr. Himawan spent 18 years at EW, where he was a Managing Director of four funds and served on numerous public and private company boards related to EW's investment activity. At EW, Dr. Himawan primarily focused on investments in therapeutic-based, pharmaceutical assets (both small molecules and also more complex biopharmaceutical compounds) and led the firm’s biotechnology practice. Through these various investments, Dr. Himawan gained an in-depth knowledge of the rapidly-growing antibody industry and the various technologies related to the discovery, manufacture, and clinical development of antibodies (both monoclonal and polyclonal).
Mr. Crouse is a Managing Director of Park Lane.
Mr. Crouse has over 40 years of experience as a healthcare venture capitalist and operating executive in the pharmaceutical and diagnostic industry. He has collaborated with EW team members on a number of companies. As Chairman or independent director of EW companies CBR 1.0, Precision Dermatology, and EUSA, he played pivotal roles in the development of those companies in the areas of general management, product acquisition, marketing and in the sale to acquirers. He created the investment opportunity for Park Lane in the successor of CBR 1.0 (“CBR 2.0”) and Precision (“Encore”) and served or continues to serve as the Chairman of both companies.